Donald B. Wender

1.8k total citations
31 papers, 1.1k citations indexed

About

Donald B. Wender is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Donald B. Wender has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Donald B. Wender's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Neuroendocrine Tumor Research Advances (5 papers). Donald B. Wender is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and Neuroendocrine Tumor Research Advances (5 papers). Donald B. Wender collaborates with scholars based in United States, India and Canada. Donald B. Wender's co-authors include Charles L. Loprinzi, Jeff A. Sloan, Paul J. Novotny, John W. Kugler, Kendrith M. Rowland, C Ghosh, Shaker R. Dakhil, Harold E. Windschitl, Daniel A. Nikcevich and Ralph Levitt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Donald B. Wender

30 papers receiving 1.1k citations

Peers

Donald B. Wender

ONCOL

PHYSI

MB

PRM

PHEOH

Fade Mahmoud United States

John C. Michalak United States

Hiroaki Ikesue Japan

Kunihiko Ishitani Japan

Harry E. Hynes United States

Giorgio Astara Italy

Roberto Vita Italy

Nikolaos Spyrou United States

Juan José López Gómez Spain

Ling Jiang China

Fade Mahmoud United States

Donald B. Wender

701 ×1.2

ONCOL

306 ×0.9

PHYSI

403 ×1.4

MB

193 ×1.1

PRM

96 ×0.8

PHEOH

Citations per year, relative to Donald B. Wender Donald B. Wender (= 1×) peers Fade Mahmoud

Countries citing papers authored by Donald B. Wender

Since Specialization

Citations

This map shows the geographic impact of Donald B. Wender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald B. Wender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald B. Wender more than expected).

Fields of papers citing papers by Donald B. Wender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald B. Wender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald B. Wender. The network helps show where Donald B. Wender may publish in the future.

Co-authorship network of co-authors of Donald B. Wender

This figure shows the co-authorship network connecting the top 25 collaborators of Donald B. Wender. A scholar is included among the top collaborators of Donald B. Wender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald B. Wender. Donald B. Wender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Inwards, David J., Paul A. S. Fishkin, Betsy LaPlant, et al.. (2014). Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Annals of Oncology. 25(10). 2020–2024. 20 indexed citations

2.

Brown, Lindsay C., Pamela J. Atherton, M.A. Neben-Wittich, et al.. (2013). Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Supportive Care in Cancer. 21(10). 2869–2877. 4 indexed citations

3.

Inwards, David J., Paul A. S. Fishkin, Betsy LaPlant, et al.. (2012). Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma. Blood. 120(21). 3661–3661. 2 indexed citations

4.

Dy, Grace K., Shauna L. Hillman, Kendrith M. Rowland, et al.. (2010). A front‐line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer. Cancer. 116(24). 5686–5693. 35 indexed citations

5.

Jatoi, Aminah, Shaker R. Dakhil, Jeff A. Sloan, et al.. (2010). Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Supportive Care in Cancer. 19(10). 1601–1607. 42 indexed citations

6.

Bryce, Alan H., Bassam Mattar, Shauna L. Hillman, et al.. (2010). Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer. American Journal of Clinical Oncology. 33(4). 353–357. 5 indexed citations

7.

Jaeckle, Kurt A., Karla V. Ballman, Caterina Giannini, et al.. (2010). Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. Journal of Neuro-Oncology. 99(1). 73–80. 5 indexed citations

8.

Grothey, Axel, Daniel A. Nikcevich, Jeff A. Sloan, et al.. (2009). Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial. Journal of Clinical Oncology. 27(15_suppl). 4025–4025. 4 indexed citations

9.

Nikcevich, Daniel A., Axel Grothey, Jeff A. Sloan, et al.. (2008). Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. Journal of Clinical Oncology. 26(15_suppl). 4009–4009. 29 indexed citations

10.

Croghan, Ivana T., R. Douglas Hurt, Shaker R. Dakhil, et al.. (2007). Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention. Mayo Clinic Proceedings. 82(2). 186–195. 51 indexed citations

11.

Garces, Yolanda I., Scott H. Okuno, Steven E. Schild, et al.. (2007). Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 67(4). 995–1001. 10 indexed citations

12.

Jatoi, Aminah, Shaker R. Dakhil, Phuong Nguyen, et al.. (2007). A placebo‐controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome. Cancer. 110(6). 1396–1403. 105 indexed citations

13.

Croghan, Ivana T., R. Douglas Hurt, Shaker R. Dakhil, et al.. (2007). Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention. Mayo Clinic Proceedings. 82(2). 186–195. 41 indexed citations

14.

Schild, Steven E., James A. Bonner, Shauna L. Hillman, et al.. (2007). Results of a Phase II Study of High-Dose Thoracic Radiation Therapy With Concurrent Cisplatin and Etoposide in Limited-Stage Small-Cell Lung Cancer (NCCTG 95-20-53). Journal of Clinical Oncology. 25(21). 3124–3129. 50 indexed citations

15.

Dy, Grace K., James R. Jett, Francois J. Geoffroy, et al.. (2006). Topotecan and Paclitaxel in Previously Treated Patients with Relapsed Small Cell Lung Cancer: Phase II Trial of the North Central Cancer Treatment Group. Journal of Thoracic Oncology. 1(3). 211–217. 5 indexed citations

16.

Clark, Matthew M., R. Douglas Hurt, Ivana T. Croghan, et al.. (2005). The prevalence of weight concerns in a smoking abstinence clinical trial. Addictive Behaviors. 31(7). 1144–1152. 99 indexed citations

17.

Marschke, Robert F., Joseph P. Grill, Jeff A. Sloan, et al.. (1999). Phase II Study of High-Dose Somatostatin Analogue in Patients Either Previously Treated or Untreated Who Have Extensive-Stage Small Cell Lung Cancer. American Journal of Clinical Oncology. 22(1). 15–17. 18 indexed citations

18.

Pitot, Henry C., Donald B. Wender, Matthew J. O’Connell, et al.. (1997). Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.. Journal of Clinical Oncology. 15(8). 2910–2919. 220 indexed citations

19.

Ellison, Neil M., Charles L. Loprinzi, J Kugler, et al.. (1997). Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients.. Journal of Clinical Oncology. 15(8). 2974–2980. 122 indexed citations

20.

Loprinzi, Charles L., Donald B. Wender, Michael H. Veeder, et al.. (1994). Inhibition of 5 - fluorouracil-induced ocular irritation by ocular ice packs. Cancer. 74(3). 945–948. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact